During this webinar, Dr. Yan's presentation will review the clinical implications of Estrogen Receptor (ER) discordance, mechanism of Cerianna positron emission tomography (PET) imaging, and the clinical applications of Cerianna PET/CT imaging. She will also identify patients who may benefit from Cerianna PET/CT imaging and review cases that demonstrate how determining full-body ER + lesions status may impact patient care.
Learning Objectives:
- Learn about the clinical implications of Estrogen Receptor (ER) discordance
- Understand the mechanism of Cerianna positron emission tomography (PET) imaging
- Recognize the clinical applications of Cerianna PET/CT imaging
- Identify patients who may benefit from Cerianna PET/CT imaging
- Review cases that demonstrate how determining full-body ER + lesions status may impact patient care
INDICATIONS AND USAGE
CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
Limitations of Use
Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).
CONTRAINDICATIONS
None.
ADVERSE REACTIONS
In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate less than 1%: were injection-site pain and dysgeusia.
To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE Healthcare Company at +1.800.654.0118 or FDA at 1-800-FDA[1]1088 or www.fda.gov/medwatch.
For full Prescribing Information please visit: [ Ссылка ]
